Werewolf Therapeutics, Inc.

NASDAQ:HOWL

Biotechnology

Healthcare
$1.03 +6.12%

+$0.06 today

Market cap
$50.06M
Beta
0.29
P/E (TTM)
-1.4
EPS (TTM)
-$0.71
52W Low $0.27High $1.83

Volume 1.85M

Average 5.09M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$60.29M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$6.03M

FY 2025 · Annual

-53.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.98M)(53.81M)(37.37M)(70.52M)(60.82M)
Depreciation & Amortization216K1.1M1.76M1.81M1.63M
Deferred Income Tax00000
Stock-Based Compensation4.1M7.4M8.01M8.83M6.25M
Change in Working Capital2.28M2.54M(5.89M)2.53M(8.21M)
Accounts Receivables0(6.93M)5.58M1.35M0
Inventory06.93M000
Accounts Payables1.01M(883K)(4.34M)3.46M(7.5M)
Other Working Capital1.27M3.42M(7.14M)(2.28M)(707K)
Other Non-Cash Items519K2.17M878K1.16M856K
Operating Cash Flow(42.88M)(40.6M)(32.61M)(56.19M)(60.29M)
Capital Expenditures(498K)(3.61M)(769K)(254K)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(498K)(3.61M)(769K)(254K)0
Debt Repayment0040M(10M)0
Common Stock Issued111.6M15.74M18.33M23.58M6.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.17M)166K100K(496K)0
Financing Cash Flow109.43M15.91M58.43M13.08M6.03M
Effect of Forex Changes00000
Net Change in Cash66.05M(28.3M)25.05M(43.36M)(54.26M)
Free Cash Flow(43.37M)(44.21M)(33.38M)(56.44M)(60.29M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$60.8M
+ D&A$1.6M
+ Stock-Based Comp$6.2M
+ Deferred Tax$0
- Working Capital-$8.2M
+ Other Non-Cash$856.0K
= Operating Cash Flow-$60.3M
- Capex$0
= Free Cash Flow-$60.3M

Analysis

FY2025 free cash flow is -$60.3M. FCF conversion is 99.1% of net income. Operating cash flow was -$60.3M, with capex of $0. The largest bridge item is Working Capital at -$8.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 16, 2026
10-QQuarterly reportNov 13, 2026
EFFECTEFFECT filingNov 12, 2026
424B3424B3 filingNov 12, 2026
S-4/AS-4/A filingNov 10, 2026

Does HOWL generate free cash flow?

Werewolf Therapeutics, Inc. (HOWL) generated -$60.29M of free cash flow in fiscal 2025.

How much operating cash flow does HOWL produce?

Operating cash flow was -$60.29M, before capital expenditures of $0.00.